Zemin Kuang
Beijing Anzhen Hospital, Capital Medical University, Beijing, China
Changes in arterial vessel function based on pulse wave analysis in the 130-139/80-89 mmHg blood pressure population: Prospective cohort and intervention study
#Cardiovascular
How will the SphygmoCor® technology enable, enhance, or accelerate your research?
The study will use the SphygmoCor non-invasive instrument for pulse wave analysis, using the brachial-ankle pulse wave velocity (baPWV) to assess the progression of arteriosclerosis and analyze the causal relationship between pulse wave parameters and endpoint events.
Executive Summary
Method: This study is a randomized, blind endpoint evaluation of a randomized controlled trial and prospective cohort study. A total of 3,012 participants with blood pressure levels of 130-139/80-89 mmHg will be selected from various community health service centers in Beijing and randomly assigned in a 1:1 ratio to an intervention group (receiving RAS Inhibitors + health education) and a control group (receiving health education). The baseline characteristics of the two groups will be similar to minimize confounding factors, with follow-ups every three months. The study will use the SphygmoCor non-invasive instrument for pulse wave analysis, using the brachial-ankle pulse wave velocity (baPWV) to assess the progression of arteriosclerosis and analyze the causal relationship between pulse wave parameters and endpoint events. Objective: To evaluate the causal relationship between changes in arterial vessel function and cardiovascular disease outcomes in the 130-139/80-89 mmHg population; to explore whether pharmacological intervention in this population can delay or halt the progression of arteriosclerosis.
Research Setting
The applicant, Kuang Zemin, holds a Ph.D. in internal medicine, serves as an associate professor, chief cardiologist, and a master's degree supervisor. Hypertension Center of the Cardiology Department at Beijing Anzhen Hospital, affiliated with Capital Medical University. Focus on exploring new models of hypertension prevention and treatment using "artificial intelligence + wearable devices." Center on gain indices and medical artificial intelligence studies. Has led or participated in 8 national-level projects, authored or co-authored 8 books, holds 7 software copyrights, has applied for 10 patents, and has published over 60 papers, including 12 as the first or corresponding author in SCI-indexed journals. Liu Hong, The Capital Health Development research project - "Establishment of a prediction model for drug Compliance Behavior of Hypertension patients in community" (Project number: 2018-3P-7052, and rated as excellent), main participant; Science and Technology Plan project of Tongzhou District, Beijing - "Analysis of Influencing Factors of drug compliance of Hypertension patients in community" (Project number: KJ2022CX087), host. Published as first author or co-author: A Clinical Prediction Model of Medication Adherence in Hypertensive Patients in a Chinese Community Hospital in Beijing. Am J Hypertens. 2020 Nov 3;33(11):1038-1046.